Wellbeing Digital Sciences Provides Commercial and Corporate Updates for KGK Science

VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO:MEDI) (OTC:KONEF) (FRA:SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research, is pleased to provide a commercial and corporate update regarding the recent achievements of its wholly-owned subsidiary, KGK Science Inc., (“KGK” or the “CRO”). The first quarter of 2022 has delivered significant opportunities for KGK as new contracts have been signed, clinical research reports have been completed, regulatory approvals have been obtained and other honours have been bestowed upon the CRO.